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An observational cross-sectional study was conducted in a national facioscapulohumeral
muscular dystrophy (FSHD) expertise center to estimate the penetrance of FSHD1 and to
evaluate phenotype–genotype correlations.
Methods
Ten FSHD1 probands carrying 4–9 D4Z4 unit alleles and 140 relatives were examined. All 150
participants were genetically characterized, including D4Z4 methylation levels in the mutation
carriers. Mutation carriers were classified as (1) symptomatic: with symptoms of muscle
weakness on history and muscle FSHD signs on examination; (2) asymptomatic: without
symptoms of muscle weakness but with muscle FSHD signs on examination; and (3) non-
penetrant: without symptoms of muscle weakness on history and without muscle FSHD signs
on examination. We assessed the relationship between age-corrected clinical severity score and
repeat size, sex, and D4Z4 methylation levels.
Results
The maximum likelihood estimates of symptomatic and those of symptomatic plus asymp-
tomatic FSHD showed that penetrance depends on repeat size and increases until late adult-
hood. We observed many asymptomatic carriers with subtle facial weakness with or without
mild shoulder girdle weakness (25% [17/69]). Nonpenetrance was observed less frequently
than in recent population studies (17% [12/69]), and most asymptomatic patients reported
some shoulder pain. D4Z4 methylation tended to be lower in moderately to severely affected
mutation carriers with 7 or 9 repeats.
Discussion
This family-based study detected a lower overall nonpenetrance than previously observed,
probably due to many asymptomatic mutation carriers identified by careful examination of
facial and shoulder muscles. The recognition of asymptomatic mutation carriers is essential for
selection of participants for future trials, and the likelihood estimates are helpful in counseling.
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Facioscapulohumeral muscular dystrophy (FSHD) type 1
(MIM 158,900) is one of the most common inherited adult
muscular dystrophies characterized by progressive, often
asymmetric muscle weakness.1,2 FSHD is in most cases as-
sociated with a contraction (1–10 units) of the polymorphic
D4Z4 macrosatellite repeat in the chromosome 4q sub-
telomere. This leads to the production of the transcription
factor DUX4 with numerous downstream myotoxic effects
leading to muscular dystrophy.3,4 In control individuals, the
D4Z4 array ranges between 11 and 100 units, a size range in
which the D4Z4 embedded DUX4 gene is repressed by CpG
methylation and other epigenetic modifications. DUX4 de-
repression in FSHD is caused either by a contraction to 1–10
D4Z4 units on a 4qA-specific FSHD-permissive haplotype
(FSHD1) or by mutations in D4Z4 chromatin repressors
SMCHD1 or DNMT3B in combination with a moderately
sized D4Z4 repeat (11–20 units) on a 4qA allele (FSHD2).5–7
FSHD-permissive 4qA haplotypes are defined by the presence
of a polymorphic DUX4 polyadenylation signal, which is
necessary for DUX4 RNA stabilization in somatic tissue.
Clinically, FSHD1 and FSHD2 are largely indistinguishable.8
In the premolecular era, estimation of penetrance of FSHD
was based on clinical diagnostic criteria and examination of
large pedigrees, which, in retrospect, were FSHD1 families.
Disease presentation was considered age-dependent with al-
most complete (>95%) penetrance by the age of 20.1,9 These
studies showed an approximately equal distribution of af-
fected and nonaffected sibs in completely examined large
sibships. With autosomal dominant inheritance and a 50%
chance of carrying the mutation, this left little room for
nonpenetrance. However, selected families were fairly large,
with many sibs with clinically evident FSHD, as the authors
were interested in linkage studies. Furthermore, follow-up
genetic studies showed that patients in these studies carried
mutations with moderate D4Z4 contractions (4–8 units).
This selection bias is likely to have contributed to the assumed
high penetrance by the age of 20.
More recent genetic studies have shown penetrance to be
incomplete even at older age, with nonpenetrance of
32%–53% dependent on repeat size and degree of
kinship.10–14 In addition, a recent study in the general pop-
ulation has shown a 1%–2% prevalence of a contracted D4Z4
repeat on a permissive 4qA haplotype without an FSHD family
history.5,15
Together, these studies point to a role for additional caus-
ative (epigenetic) mechanisms contributing to developing
FSHD1. This is supported by the observation that very large
pedigrees of this apparently nonlethal disease are less com-
mon than would be expected based on the high mutation
frequency and the high prevalence of the permissive haplo-
type.16 One of these epigenetic mechanisms includes the
degree of D4Z4 methylation, which was not assessed in the
population studies discussed above.10–14 Our recent studies
have shown that D4Z4 methylation significantly correlates
with repeat size, but is also likely to be modified by variants
of known and unknown chromatin modifiers, especially af-
fecting the severity in individuals with repeats of 8–10
units.3,5,7,17
We performed a cross-sectional, observational single-center
study in 10 families with at least 2 affected family members,
encompassing 10 probands and 140 first-, second-, and third-
degree relatives. We aimed to estimate penetrance for FSHD1
for different repeat lengths and ages. Different from other
population studies, we distinguished between (1) mutation
carriers with muscle symptoms on history and muscle FSHD
signs on examination (symptomatic carriers); (2) mutation
carriers without muscle symptoms but with muscle signs of
FSHD on examination (asymptomatic carriers); and (3)
mutation carriers without muscle symptoms on history and
without muscle FSHD signs on examination (nonpenetrant
carriers). In addition, we assessed the relationship between
age-corrected clinical severity score (CSS) and repeat size,
sex, and D4Z4 methylation levels.
Methods
Standard protocol approvals, registrations,
and patient consents
The study protocol was approved by the local medical ethics
committee and informed consent was obtained from all par-
ticipants (CMO 2001/031).
Outcome measures
The primary outcome measures were the maximum likeli-
hood estimates of symptomatic and symptomatic plus
asymptomatic FSHD. The secondary outcomemeasures were
the relationships between age-corrected CSS and repeat size,
sex, and D4Z4 methylation levels.
Patients
We recruited 11 genetically confirmed FSHD1 probands from
families with at least 2 adult affected members. This excluded
probands with D4Z4 repeats <4 units as they are frequently
unique cases. One family with compound heterozygous
contracted D4Z4 allele was excluded, resulting in 10 pro-
bands. We aimed to examine all available adult first-, second-,
and third-degree family members irrespective of their clinical
condition by home visits. Obligate mutation carriers not in-
cluded in this study were defined as family members with
Glossary
CSS = clinical severity score; FSHD = facioscapulohumeral muscular dystrophy type 1; PFGE = pulsed field gel electrophoresis.
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genetically confirmed FSHD (in a diagnostic setting) or
family members with offspring with genetically confirmed
FSHD, both of whom were not able or willing to participate.
Clinical evaluation
All participants filled out a questionnaire on symptoms and
signs of FSHD, including age at onset, initial and current
weakness of facial, shoulder, and pelvic girdle, and foot ex-
tensor muscles. They were also questioned about other
symptoms and their medical history and medication use. All
participants were examined by the same well-trained observer
(M.W.). Mutation carriers were classified as “symptomatic,”
“asymptomatic,” and “nonpenetrant” as defined above. Mus-
cle FSHD signs included both weakness and atrophy and
related signs (incomplete forceful eye closure “signe de cils,”
scapular winging, poly hill sign, horizontal axial folds, and
Beevor sign).2,18 Facial weakness was scored as 0–2: 0 = no
weakness; 1 = moderate weakness; 2 = severe weakness of the
orbicularis oculi or oris muscles or the zygomaticus major
muscles. Shoulder and pelvic girdle and foot extensor muscles
were tested using manual muscle testing. In addition, subtle
shoulder girdle weakness was specifically tested by repetition
of slowly lowering the arms forwards and sideward (after
maximal shoulder anteflexion and abduction). Clinical se-
verity was also scored using the CSS and the age-corrected
CSS.19 When a discrepancy was found between clinical ob-
servation and the genetic test, participants were evaluated by
a second observer (G.W.P.) who was blinded for these results.
Genetic testing
All participants were analyzed for D4Z4 repeat size, haplo-
type, and D4Z4 methylation. Genomic DNA was isolated
from peripheral bloodmononuclear cells and detailed analysis
of the D4Z4 repeat sizes and haplotype on chromosomes 4
and 10 was done by pulsed field gel electrophoresis (PFGE)
and PCR as described.20 Further haplotype analysis was done
by Southern blot hybridization with probes A and B and by
analysis of simple sequence length polymorphism according
to previously described protocols.20
Repeat array sizes ranging from 20 to 60 kb (4–16 units) were
accurately determined using a modified PFGE program spe-
cific for fragment sizes between 5 and 75 kb and by adding
a 5-kb molecular weight marker to each lane of the genomic
DNA samples (Bio-Rad, Hercules, CA, 170–3,624).17 D4Z4
methylation was established at the FseI restriction site in the
most proximal unit of the 4 D4Z4 repeat arrays as described
previously.6 We used the delta1-methylation value, which is
the difference between the predicted D4Z4 methylation level
based on the repeat size and the observed methylation level.17
Control individuals andmutation carriers with an FSHD allele
shorter than 7 units generally have delta1-methylation values
between −10 and +10%. For mutation carriers with 7–10 unit
FSHD alleles, the delta1-methylation value is more variable,
which has been suggested to contribute to the variation in
clinical severity.17,21 For FSHD2 patients, delta1-methylation
values typically range between −21% and −45%.
Estimation of penetrance and
genotype–phenotype correlations
The demographic, clinical, and genetic data were recorded as
variables in a SPSS database (SPSS version 22, SPSS, Chicago,
IL). Symptomatic mutation carriers had a self-reported age at
onset preceding the age at examination. The age at onset of
asymptomatic FSHD was unknown; by definition, it precedes
the age at examination (age at onset is interval censored, type
I). Nonpenetrant mutation carriers have an unknown age at
onset that is always later than the age at examination (right-
censored).
We determined the maximum likelihood estimates of the
penetrance of symptomatic and symptomatic plus asymp-
tomatic FSHD for 5, 6, 7, 8, and 9 D4Z4 units (from up to
down) for age (figure 1). This represents the likelihood of
reported symptoms by a patient at a certain age (symptomatic
mutation carriership) and of reported symptoms by patients
or observed signs by the neurologist at a certain age (symp-
tomatic and asymptomatic mutation carriership). Both
penetrances were modeled as Cox regression models with
Figure 1 Penetrance for each contraction size
Total number of facioscapulohumeral muscu-
lar dystrophy type 1 allele carriers grouped by
repeat size in units and sorted by clinical status
(symptomatic, asymptomatic and non-
penetrant mutation carriers).
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a Weibull baseline distribution and the logarithm of the
number of D4Z4 units as a covariate. We estimated the un-
known measures in the model by maximizing the conditional
likelihood (by means of a grid search); the likelihood is
conditional on the ascertainment event to correct for the
selection of families (at least 2 known symptomatic mutation
carriers).
The analysis thus (1) corrected for the selection of families
with at least 2 known symptomatic mutation carriers; (2)
distinguished for different repeat lengths with a presumed
correlation to disease severity; and (3) took into account the
unknown age at onset of asymptomatic mutation carriers. No
correction for other factors that may influence disease severity
(environmental, methylation, and epigenetic factors) was in-
cluded. The R-code and mathematical calculations can be
obtained on request by the corresponding author (Nicol
Voermans, unpublished data, December 22, 2017).
Correlation between repeat length and age-corrected CSS was
calculated with the Spearman correlation coefficient. We
assessed the relationship between age-corrected CSS and re-
peat size, sex, and delta1-methylation value by linear re-
gression analysis (without correction for other environmental
and epigenetic factors that may influence CSS). The delta1-
methylation value of mildly and severely affected patients
(age-corrected CSS <50 and age-corrected CSS ≥50) was
visualized in a graph.
Data availability
Anonymized data not published within this article will be
made available by request from any qualified investigator.
Results
Participants
We studied 10 families and invited 197 family members (95
male). Data are available from Dryad Pedigrees, doi.org/10.
5061/dryad.cj4c2s1. Forty-seven family-members (29
male) were not able to participate for various reasons (living
abroad, having lost contact with their family, or not willing
to participate). Three of them were obligate mutation car-
riers. Hence, 10 probands (5 male) and 140 relatives were
included (66 male), resulting in an inclusion rate of 76%.
The median age was 44.5 years (range 18–85 years) (table 1:
features of FSHD mutation carriers; table 2: distribution of
mutation carriers and noncarriers by D4Z4 allele size in
units).
Genetic analysis identified 69 FSHD1 mutation carriers (28
male), of which 40 were symptomatic (10 probands [5
male] and 30 relatives [11 male]), 17 were asymptomatic (8
male), and 12 were nonpenetrant (4 male). This corre-
sponded with a false-negative rate of the clinical assessment
of 13% (12/89). In 4 nonmutation carriers, we observed
mild asymmetrical weakness of the facial (n = 2) or shoulder
muscles with shoulder pain (n = 2). These 4 participants
were incorrectly scored by both examiners as asymptomatic
with a CSS of 1 or 2 (CSS 1: facial weakness only; CSS 2:
mild scapular weakness; no limitations of abduction or el-
evation; often asymptomatic). One of them was diagnosed
before with idiopathic adhesive capsulitis of the shoulder,
and one with rheumatoid arthritis. The other 2 showed very
subtle facial weakness. Hence, the false-positive rate of
clinical assessment for detection of the carrier status was 5%
(4/81) (table 3: results of clinical assessment and genetic
analysis).
The pedigrees of these 10 families are deposited in Dryad
(Data Dryad Digital Repository, doi:10.5061/dryad.cj4c2s1).
Clinical evaluation
The variation in estimated age at onset based on the recol-
lection was large (median 20.0; range 10–60 years). Shoulder
girdle weakness was the most frequent initial and current
symptom (85%; 34 of the 40 symptomatic mutation carriers)
(table 4: characteristics of individual patients). Pain, both
chronic and episodic, was reported by 33 of the 40 symp-
tomatic carriers, predominantly in shoulder, neck, and lower
back region. Strikingly, 10 of the 17 asymptomatic carriers
spontaneously reported shoulder girdle pain. Eight of these 10
had mild weakness of the shoulder girdle muscles (asym-
metrical movement of the scapula); the other 2 young female
patients only had mild facial weakness.
The questionnaires on concomitant diseases and medication
use showed no malignancies, and no remarkable other
comorbidity or medication use. Four female mutation carriers
reported worsening of the weakness after pregnancies or after
Table 1 Features of facioscapulohumeral muscular
dystrophy (FSHD) type 1 mutation carriers
(symptomatic, asymptomatic, and
nonpenetrant)
Features of FSHD mutation carriers (age 18 and above)
Values
(n = 69)
Sex, M/F, n (%) 28 (41)/41
(59)
Age, y, median 44.5
Age at onset (patient-reported; symptomatic patients
only, n = 40), y, median (range)
20.0 (8–60)
Symptomatic mutation carriers, n (%) 40 (58)
Asymptomatic mutation carriers, n (%) 17 (25)
Nonpenetrant mutation carriers, n (%) 12 (17)
Repeat size, units, range 4–9
Repeat size, kB, range 20–38
Delta1-methylation value, range −29.9 to
11.3
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menopause, and 2 mutation carriers reported a positive effect
on muscle weakness when taking oral contraceptives. How-
ever, the number of female mutation carriers was too small to
analyze correlation with hormonal effects.
Results of clinical examination are shown in table 2; overall, 40
mutation carriers were symptomatic (58%), 17 asymptomatic
(25%; 26% in 4–6 units; 23% in 7–9 units), and 12 had neither
symptoms nor signs of muscle weakness (nonpenetrant
Table 3 Results of clinical assessment and genetic analysis
Clinical assessment:
number of patients














Genetic test: number of patients with negative
test (repeat length >10 D4Z4 units)
77 4 81 False-positive clinical
assessment: 4/81 (5%)
Genetic test: number of patients with positive
test (repeat length 1–10 D4Z4 units)
12 57 69
Total number of patients




Abbreviation: FSHD = facioscapulohumeral muscular dystrophy.


























4 206 12 (3) 4 (0) 8 (3) 3 (1) 5 (2) 0 0 5 (2)
Total 206 12 (3) 4 (0) 8 (3) 3 (1) 5 (2) 0 0 5 (100%) (2)
5 202 25 (7) 5 (3) 20 (4) 11 (4) 9 (0) 0 0 9 (0)
5 203 23 (13) 9 (4) 14 (9) 6 (3) 8 (6) 0 1 (0) 7 (6)
Total 202–203 48 (20) 14 (7) 34 (13) 17 (7) 17 (6) 0 1 (6%) (0) 16 (94%) (6)
6 205 15 (6) 4 (2) 11 (4) 6 (2) 5 (2) 0 0 5 (2)
6 207 17 (7) 1 (1) 16 (6) 9 (3) 7 (3) 0 5 (2) 2 (1)
6 208 47 (27) 14 (11) 33 (16) 20 (10) 13 (6) 4 (2) 6 (4) 3 (0)
Total 205–208 79 (40) 19 (14) 60 (26) 35 (15) 25 (11) 4 (16%) (2) 11 (44%) (6) 10 (40%) (3)
7 201 17 (10) 3 (3) 14 (7) 9 (5) 5 (2) 1 (0) 1 (0) 3 (2)
7 289 8 (5) 0 8 (5) 5 (3) 3 (2) 0 1 (1) 2 (1)
Total 201–298 25 (15) 3 (3) 22 (12) 14 (8) 8 (4) 1 (13%) (0) 2 (25%) (1) 5 (62%) (3)
9 209 21 (11) 4 (4) 17 (7) 9 (5) 8 (2) 4 (0) 2 (1) 2 (1)
9 210 12 (6) 3 (1) 9 (5) 3 (2) 6 (3) 3 (2) 1 (0) 2 (1)
Total 209–210 33 (17) 7 (5) 26 (12) 12 (7) 14 (5) 7 (50%) (2) 3 (21%) (1) 4 (29%) (2)
Total
4–9
197 (95) 47 (29) 150 (66) 81 (38) 69 (28) 12 (17%) (4) 17 (25%) (8) 40 (58%) (16)
Invited subjects through the proband (participants plus nonparticipants); participants: invited family members participating in the study; nonparticipants:
invited familymembers not participating in the study; obligatemutation carriers: nonparticipants with a D4Z4 contraction. Noncarriers: familymembers with
a D4Z4 contraction of >10 units; carriers: family members carrying a contracted D4Z4 allele segregating in their family. Symptomatic carriers: mutation
carriers with symptoms and signs of FSHD; asymptomatic carriers: mutation carriers without symptoms but with signs of the disease. Nonpenetrant:
mutation carriers without symptoms and without signs of facioscapulohumeral muscular dystrophy.
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Table 4 Characteristics of individual patients
Pedigree number corresponding
with the supplemental pedigrees M/F D4Z4 FseI delta1 AAE AAO CSS (status) ACSS F SG E p
Family 206 (n = 5)
307 M 4 43 2.7 45 10 5 (S) 111 R R R
204 F 4 43 5.2 71 20 8 (S) 113 L L LR LR
206a M 4 28 0.5 55 15 7 (S) 127 R R R R
316 F 4 26 −6.0 29 15 7 (S) 241 L R R R
208 F 4 26 −10.6 53 15 6 (S) 113 R R LR
Family 202 (n = 9)
406 F 5 39 4.3 41 20 5 (S) 122 R LR R
306 F 5 41 1.0 73 50 2 (S) 27 R R R
308a F 5 29 −8.3 70 15 8 (S) 114 R R R R
414 F 5 48 5.9 42 20 4 (S) 95 R R LR
310 F 5 45 7.7 68 20 8 (S) 118 L R LR R
312 F 5 46 8.7 63 15 7 (S) 111 R R LR R
422 F 5 31 3.7 42 20 7 (S) 167 R R R R
424 F 5 29 −6.1 39 20 6 (S) 154 R R R R
426 F 5 18 −9.3 35 15 7 (S) 200 R L L L
Family 203 (n = 8)
305 M 5 28 −4.5 61 35 7 (S) 115 L L LR L
307b Mb 5b
309a M 5 40 1.0 58 30 7 (S) 121 L L L LR
409 M 5 21 −14.6 33 20 3 (S) 91 R R
414 F 5 33 −6.8 30 0 (AS) 0
313 M 5 35 −1.8 53 30 6 (S) 113 R L R R
421 M 5 48 2.7 22 15 4 (S) 182 L L
423 M 5 42 −2.1 20 15 3 (S) 150 R R
214 F 5 46 11.3 85 60 8 (S) 94 R R LR LR
Family 205 (n = 5)
403 M 6 NA NA 27 15 3 (S) 111 R R
304 F 6 12 −20.1 58 25 5 (S) 86 R R R LR
408 F 6 15 −13.5 25 20 2 (S) 80 R R
203 M 6 28 −6.0 86 40 8 (S) 93 R R LR R
310a F 6 22 −9.1 49 10 8 (S) 163 R R L L
Family 207 (n = 7)
204a F 6 39 4.8 55 35 8 (S) 145 L L L LR
308 F 6 33 2.3 32 4 (AS) 125 L L L
312 F 6 NA NA 25 2 (AS) 80 R R
205 M 6 23 −2.5 51 50 5 (S) 98 R R LR
313 M 6 29 −7.1 29 2 (AS) 69 R
Continued
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Table 4 Characteristics of individual patients (continued)
Pedigree number corresponding
with the supplemental pedigrees M/F D4Z4 FseI delta1 AAE AAO CSS (status) ACSS F SG E p
321 M 6 24 −12.1 20 1 (AS) 50 R
324 F 6 33 −2.6 18 2 (AS) 111 L L
Family 208 (n = 13)
202 F 6 28 −12.1 60 40 5 (S) 83 R L L
204a F 6 NA NA 58 30 9 (S) 155 L R L LR
314 F 6 35 −4.7 30 0 (NP) 0
206 F 6 41 2.4 56 1 (AS) 18 R R
318 F 6 43 1.3 30 0 (NP) 0
211 M 6 36 3.2 49 0 (AS) 0
327 M 6 30 −9.0 20 0 (NP) 0
220 F 6 42 4.6 44 40 3 (S) 68 L R
223 M 6 34 −7.4 43 2 (AS) 47 L R
225 M 6 38 −1.2 42 2 (AS) 48 R
248 F 6 32 −0.7 47 2 (AS) 43 R L
355 M 6 36 −4.5 21 2 (AS) 95 L L
358 M 6 38 −5.2 19 0 (NP) 0
Family 201 (n = 5)
309 M 7 18 −20.9 63 40 9 (S) 143 L R R LR
420 F 7 48 9.5 34 0 (NP) 59 L L
422 F 7 38 −0.5 32 2 (AS) 0 L
314 F 7 38 −6.6 57 25 8 (S) 140 R R LR R
429b Mb 7b
317a M 7 42 −2.2 53 15 7 (S) 132 R R R LR
Family 289 (n = 3)
301 M 7 43 6.0 45 3 (AS) 67 L
204 F 7 26 −13.2 72 60 1 (S) 14 L
309a M 7 43 5.9 38 30 6 (S) 158 R R R
Family 209 (n = 8)
302 F 9 36 −7.3 31 0 (NP) 0
202 F 9 37 −5.4 55 0 (NP) 0
204 F 9 31 −3.4 53 45 3 (S) 57 R
205 M 9 33 −7.9 52 2 (AS) 38 R
209a M 9 26 −8.3 49 40 6 (S) 122 R R R
314 F 9 15 −17.7 22 1 (AS) 45 LR
212 F 9 36 −1.8 44 0 (NP) 0
214 F 9 35 2.5 45 0 (NP) 0
Continued
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FSHD) (17%; 9% in 4–6 units; 36% in 7–9 units). The me-
dian CSS was 3 (range 0–9); the median age-corrected CSS
was 94 (range 0–273).
Relatives with symptomaticmuscle weaknesswho attributed this
to other disorders or aging were considered symptomatic. For
example, we observed a carrier with unilateral foot drop and
a carrier with a camptocormia, bothwithmild facial and shoulder
girdle weakness. The asymptomatic mutation carriers were
generally mildly affected (CSS 1–2) and all had at least mild
facial weakness (figure 2). We did not observe any mutation
carriers with shoulder girdle weakness without facial weakness.
Genetic testing
The disease allele size varied from 4 to 9 D4Z4 units
(20–38 kb). Seven of the 12 nonpenetrant carriers were from
2 families carrying a 9-unit repeat. Interestingly, 6 asymp-
tomatic carriers and 4 nonpenetrant carriers were found in
family Rf208 with a 5 units repeat length. Mean age of these
nonpenetrant carriers was 24.8 years (range 19–30 years),
whereas the mean age of the asymptomatic carriers in this
family was 43.0 (range 21–56 years). D4Z4methylation levels
were assessed in 66 mutation carriers and were variable with
a delta1-methylation value range of −29.9 to 11.3.
Estimated penetrance and
genotype–phenotype correlations
The maximum likelihood estimates of the penetrance for
symptomatic and symptomatic plus asymptomatic mutation
carriers showed that penetrance depends on age and repeat
size (figure 3, A and B). We observed a moderate correlation
between the age-corrected CSS and the size of the FSHD
Table 4 Characteristics of individual patients (continued)
Pedigree number corresponding
with the supplemental pedigrees M/F D4Z4 FseI delta1 AAE AAO CSS (status) ACSS F SG E p
Family 210 (n = 6)
201 M 9 6 −28.4 63 40 7 (S) 111 R R LR LR
303 M 9 29 −6.1 35 0 (NP) 0
208b Fb 9b
212a F 9 11 −29.9 52 30 7 (S) 135 R R R R
316 F 9 32 −7.6 32 2 (AS) 63 L R
317 M 9 28 −8.0 30 0 (NP) 0
104 F 9 42 −1.7 70 0 (NP) 0
Abbreviations: AAE = age at examination; AAO = age at onset of motor symptoms of facioscapulohumeral muscular dystrophy; ACSS = age-corrected clinical
severity score (CSS/age at onset × 1,000)37; AS = asymptomatic; CSS = clinical severity score × 2; D4Z4 = number of D4Z4 repeat units; delta1 = log2 delta1 (the
predicted D4Z4 methylation based on the repeat size and the observed methylation)17; E = foot extensor weakness; F = facial weakness; FseI = methylation
value at the FseI restriction site of 4q +10q alleles6; L = asymmetry ofweakness at the left side; LR = no distinct asymmetry; NO = nonpenetrant; P = pelvic girdle
muscle weakness; R = asymmetry of weakness at the right side; S = symptomatic; SG = shoulder girdle weakness;
The families are ordered according to repeat length.
a Index patient in pedigree.
b Obligate carriers who did not participate in this study.
Figure 2 Mild facioscapulohumeral muscular dystrophy features on examination in an asymptomatic patient
(A) At rest. (B) Pursing of lips shows asymmetry of the orbicularis oris muscle. (C) Forceful closing of eyes: the eyelashes do not disappear: “signe de cils.”
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allele (R = −0.48 [p < 0.01]; figure 4A). We detected large
differences between individual delta1-methylation values.
Reduced methylation tended to be associated with a more
severe phenotype (age-corrected CSS >50) in the carriers of
the large size FSHD alleles (9 units) (figure 4B). Linear
regression analysis confirmed this trend for methylation; in
contrast, sex did not contribute to age-corrected CSS
(β coefficients: −0.55 [p < 0.001], −0.224 [p = 0.06], −0.11
Figure 3 Maximum likelihood curves of the penetrance
Maximum likelihood estimates of
the penetrance of symptomatic (A)
and symptomatic plus asymptom-
atic facioscapulohumeral muscu-
lar dystrophy (FSHD) (B) for 5, 6, 7,
8, and 9 D4Z4 units (from up to
down) for age. This represents the
likelihood of reported symptoms
by the patient at a certain age (A:
symptomatic mutation carriership)
and of reported symptoms by the
patients or observed signs by the
neurologist at a certain age (B:
symptomatic and asymptomatic
mutation carriership). Both pene-
trances were modeled as Cox re-
gression models with a Weibull
baseline distribution and the loga-
rithm of the number of D4Z4 units
as a covariate. (A) Carriers with 8
repeats have a 20% (0.198) chance
of being symptomatic at age 70. (B)
Carriers of repeat size of 8 units
have only a 24% (0.236) chance of
being detected by clinical exami-
nation at age 30, which is in
agreement with our clinical expe-
rience. These likelihood estimates
are helpful in counseling; however,
the number of patients on which
the estimates are based calls for
cautiousness. (A) Maximum likeli-
hood estimates of penetrance of
symptomatic FSHD (both symp-
toms + signs). (B) Maximum likeli-
hood estimates of penetrance of
symptomatic plus asymptomatic
FSHD (only signs and both symp-
toms and signs).
Figure 4 Genotype–phenotype correlations
(A) Correlation between the size of the facioscapulohumeralmuscular dystrophy allele in units and the age-corrected clinical severity score (CSS). R = −0.48 (p < 0.01)
(Spearmanrho). (B)D4Z4methylation (delta1-methylationvalue)andclinical severity (dichotomizedage-correctedCSS) for each repeat length. Foreach repeatarray
size, we binned themutation carriers based on their age-corrected CSS (<50: mild disease severity; ≥50: moderate–severe disease severity). For carriers of a 9-unit
repeat, more severe disease tended to be associated with a lower delta1-methylation value (p = 0.06). *Mutation carriers with DNMT3B variant.
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[p = 0.92] for repeat size, methylation level, and sex,
respectively).
Family 210 is a family with a 9-unit D4Z4 allele. Three of the 6
mutation carriers in this family were clinically affected, 2 of
whom had strongly reduced delta1-methylation values
pointing to severe D4Z4 hypomethylation (patient 201:
−28.4 and patient 212: –29.9). This suggested the presence of
D4Z4 methylation modifiers. Indeed, genetic studies identi-
fied a pathogenic DNMT3B variant causing D4Z4 hypo-
methylation in this family.7
Discussion
This family-based study on penetrance in 10 probands and 140
relatives showed that prevalence of both symptomatic and
asymptomatic FSHD1 increases into late adulthood (age >60
years) (figure 3, A and B). These maximum likelihood estimates
are helpful in counseling; however, the number of patients on
which the estimates are based calls for caution. We found a high
percentage of asymptomatic mutation carriers (25% [17/69];
26% in 4–6 units; 23% in 7–9 units). Nonpenetrance of FSHD1
was lower than in recent population studies with similar age
ranges (17% [9% in 4–6 units; 36% in 7–9 units] vs 32%–52%),
most likely since nonpenetrant FSHD1 and asymptomatic
carriership were not distinguished in these studies.10–14,22 Fur-
thermore, our approach of home visits allowed more family
members to participate, resulting in inclusion of 76% of all
existing first-, second-, and third-degree family members.
All asymptomatic mutation carriers showed at least mild, mostly
asymmetric, facial weakness with or without mild shoulder
girdle weakness. This observation challenges the concept of
facial-sparing FSHD.23–27 Mild facial muscle weakness is likely
to remain unnoticed both by the patient and the physician.2
Subtle weakness of the orbicularis oculi muscles leads to a “signe
de cils”—an inability to bury the eyelashes completely when
attempting to close the eyes tightly. Asymmetrical weakness of
the orbicularis oris muscles causes asymmetrical pursing of the
lips (figure 2). This differs from the normal facial asymmetry at
rest observed in almost all healthy individuals. Hence, facial
function should be actively tested, not only assessed by in-
spection during history. Likewise, subtle shoulder girdle weak-
ness can be missed when not specifically tested by repetition of
slowly lowering the arms forwards and sideward (after maximal
shoulder anteflexion and abduction).2
We observed a moderate but significant (p < 0.01) inverse
correlation between the size of the FSHD allele and the age-
corrected CSS (figure 4A), confirming previous studies.17,28
In addition, we observed a great variability of D4Z4 methyl-
ation, both within and between families. Some moderately to
severely affected carriers (age-corrected CSS >50) of larger
FSHD alleles had very low delta1-methylation values (figure
4B). Both observations are in accordance with previous
findings.17,29–32 In patients with repeat size of 1–5 units, the
disease severity was mainly determined by the size of the
FSHD allele with a minimal role for additional epigenetic
factors.17 In contrast, in patients with 7–10 units, epigenetic
regulation of the repeat, reflected in the delta1-methylation
value, seems to co-determine the severity of FSHD.17 Fur-
thermore, in family 210, a DNMT3B variant cosegregating
with the D4Z4 contraction contributed to the severe D4Z4
hypomethylation and to clinical severity. Finally, in this
family-based study we did not find significant sex differences
in penetrance or clinical severity.17
This study also resulted in some other clinical observations.
First, we confirmed a high prevalence of pain, especially
shoulder pain, even in asymptomatic patients (75% of
symptomatic and asymptomatic patients).33–36 Second, the
observation of obviously affected mutation carriers who
reported no symptoms (family member with foot drop) or
had a very recent onset (family member with camptocormia)
illustrates the fact that retrospective estimation of age at onset
by patients is not reliable in all cases. We therefore prefer use
of the age-corrected CCS.37 Indirectly, this study confirms
that carrier status cannot be determined reliably by clinical
examination alone (5% false-positive clinical assessment; 13%
false-negative clinical assessment) and that genetic testing is
required. Furthermore, because of the gray zone of 8–10
repeats, genetic testing in families with isolated cases should
be counseled carefully as it is uncertain whether mutation
carriers represent control or nonpenetrant population.
The main limitation of this study is its cross-sectional design.
Furthermore, among the asymptomatic carriers were patients
under the age of 30, who may still be presymptomatic. This
underscores the need for longitudinal studies in FSHD.
In short, this study showed that penetrance of FSHD con-
tinues to increase in adulthood, and that nonpenetrance of
FSHD is lower than shown in recent population studies.
Penetrance and severity are related to both the number of
residual D4Z4 units and, most likely in patients with longer
repeats, to D4Z4 methylation. Assessment of family members
at risk should include questions on shoulder girdle pain and
examination of forceful eye closure, lip pouting, and in-
spection of the shoulder muscles after repeatedly and slowly
lowering maximally abducted and anteflexed arms.
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